Press Releases | Investor Relations | Eledon Pharmaceuticals, Inc.

11/12/2026	Eledon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Business Highlights
10/26/2026	Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting
10/05/2026	Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting
09/22/2026	Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society
09/09/2026	Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society
09/03/2026	Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026
08/13/2026	Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
06/25/2026	Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
06/22/2026	Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus
06/08/2026	Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine